Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.52 |
| ▸ | HTR3B | O95264 | 2/20 | 0.49 |
| ▸ | HTR3A | P46098 | 2/20 | 0.49 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.49 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.49 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10125132 | 0.86 | IDH1 (0.39) | OPRM1HTR3BHTR3AHTR3EHTR3D | |
| SCHEMBL30931073 | 0.86 | IDH1 (0.39) | OPRM1HTR3BHTR3AHTR3EHTR3D | |
| SCHEMBL16549533 | 0.85 | OPRM1 (0.42) | OPRM1HTR3BHTR3AHTR3EHTR3D | |
| SCHEMBL1492903 | 0.83 | MBOAT4 (0.40) | OPRM1HTR3BHTR3AHTR3EHTR3D | |
| SCHEMBL990450 | 0.83 | MBOAT4 (0.38) | OPRM1HTR3BHTR3AHTR3EHTR3D | |
| SCHEMBL29705743 | 0.83 | MBOAT4 (0.40) | OPRM1HTR3BHTR3AHTR3EHTR3D | |
| SCHEMBL10125131 | 0.81 | MBOAT4 (0.40) | OPRM1HTR3BHTR3AHTR3EHTR3D | |
| SCHEMBL16546661 | 0.81 | OPRM1 (0.39) | OPRM1HTR3BHTR3AHTR3EHTR3D | |
| SCHEMBL759250 | 0.81 | CA12 (0.39) | OPRM1 | |
| SCHEMBL23163387 | 0.79 | MAP3K12 (0.37) | OPRM1HTR3BHTR3AHTR3EHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2515656-B1 | AMINOBENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2014-08-06 | — | — | EP | disclosed |
| US-8383638-B2 | Aminobenzoquinazolinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383638-B2 | Aminobenzoquinazolinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME (US) | 2013-02-26 | — | — | US | disclosed |
| US-20120264761-A1 | Aminobenzoquinazolinone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME LLC | 2012-10-18 | — | — | US | disclosed |
| US-20120264761-A1 | Aminobenzoquinazolinone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME LLC | 2012-10-18 | — | — | US | disclosed |
| WO-2011084371-A1 | AMINOBENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264761-A1 | Aminobenzoquinazolinone M1 Receptor Positive Allosteric Modulators | CHRM1, OPRL1, MTNR1B | OPRM1 5/4885HTR3B 21/4885HTR3A 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.